Synthesis, Characterization, and Docking Study of Novel Thioureidophosphonate-Incorporated Silver Nanocomposites as Potent Antibacterial Agents

Solid-state tailored silver nanocomposites from chitosan: Synthesis, antimicrobial evaluation and molecular docking

This study thoroughly explores the synthesis, characterization, and antimicrobial efficacy of three α-aminophosphonate-chitosan (α-AP-Cs) compounds and their nano‑silver functionalized organic hybrids. α-AP-Cs derivatives (CU, CT and CSC) were synthesized via an in-situ, one-pot reaction using chitosan and triphenyl-phosphite, with different carbamide-glutaraldehyde crosslinkers; urea-glutaraldehyde, thiourea-glutaraldehyde and semicarbazide-glutaraldehyde, respectively. Subsequently, their corresponding α-AP-Cs‑silver nanocomposites (CU-Ag0NPs, CT-Ag0NPs and CSC-Ag0NPs) were synthesized via solid-state approach. Their physicochemical and morphological profiles were fully characterized and compared against chitosan-Ag0NPs (Cs-Ag0NPs) and their bare organic-cores via CHNS/P/O, FT-IR, XRD, TEM, EDX, XPS and UV-visible analysis. The synthesis procedure, including phosphonation and carbamide-glutaraldehyde crosslinking, was confirmed through spectroscopic and elemental analyses. XPS and XRD affirmed the metallic silver with FCC structure. The UV-visible absorption peak was ⁓399 nm with averaging TEM size of the semi-spherical Ag0NPs around 30.4 nm. Thereafter, antimicrobial properties were systematically explored and optimized by evaluating minimum inhibition concentration, dose-killing, growth kinetics curves, protein leakage, and antibiofilm activity against bacterial strains (Streptococcus mutans and Pseudomonas aeruginosa) and fungal strains (Candida albicans and Rhizopus oryzae). Notably, incorporating α-aminophosphonate and Ag0NPs into chitosan-backbone markedly enhanced its antimicrobial efficacy against bacterial and fungal biofilms. Finally, a detailed structure-activity relationship study was conducted to elucidate the antimicrobial mechanisms.

Inhibition of DRP-1 mitochondrial mitophagy and fission by novel α-aminophosphonates bearing pyridine: synthesis, biological evaluations, and computer-aided design

Heterocyclic compounds play a crucial role in the drug discovery process and development due to their significant presence and importance. Here, we report a comprehensive analysis of α-aminophosphonates containing pyridine (3a-g), prepared according to a clear-cut, uncomplicated procedure. The phosphonates are thoroughly characterized using various methods, such as elemental analysis, mass spectrometry, proton and carbon NMR, and FT-IR. The molecular docking interactions between the phosphonate and DRP-1 target protein observed that compound 3d had the top-ranked binding energy towards DRP-1 with a value equal to - 9.54 kcal/mol and this theoretically proves its inhibitory efficacy against DRP-1 arbitrated mitochondrial fission. Besides, the anticancer characteristics of compound 3d showed the best IC50 against HepG-2, MCF-7, and Caco-2 which confirmed our results towards suppressing DRP-1 protein (in-silico), and it elucidated no cytotoxic effects against human normal cell line (WI-38). Further, its pharmacokinetics were observed theoretically using ADMET. Moreover,compound 3d investigated the most potent antimicrobial ability against two pathological fungal strains, A. flavus and C. albicans, and four bacterial strains, E. coli, B. subtillis, S. aureus, and P. aregeunosa. Additionally, compound 3d clarified a powerful antioxidant scavenging activity against DPPH and ABTS free radicals (in-vitro). Furthermore, Density functional theory (DFT) was used to study the molecular structures of the synthesized compounds 3a-g, utilizing 6-311++G(d,p) as the basis set and to learn more about the molecules' reactive sites, the energies of the molecular electrostatic potential (MEP), the lowest unoccupied molecular orbital (LUMO), and the highest occupied molecular orbital (HOMO) were observed. Theoretically, FT-IR and Nuclear magnetic resonance (NMR) measurements are calculated for every compound under investigation to show how theory and experiment relate. It was found that there was an excellent agreement between the theoretical and experimental data. Conclusively, all novel synthesized phosphonates could be used as pharmaceutical agents against pathogenic microbial strains and as anticancer candidates by inhibiting DRP-1-mediated mitochondrial mitophagy.

Design, synthesis, docking, and antiviral evaluation of some novel pyrimidinone-based α-aminophosphonates as potent H1N1 and HCoV-229E inhibitors

Dialkyl/aryl aminophosphonates, 3a-g and 4a-e were synthesized using the LiClO4 catalyzed Kabachnic Fields-type reaction straightforwardly and efficiently. The synthesized phosphonates structures were characterized using elemental analyses, FT-IR, 1H NMR, 13C NMR, and MS spectroscopy. The new compounds were subjected to in-silico molecular docking simulations to evaluate their potential inhibition against Influenza A Neuraminidase and RNA-dependent RNA polymerase of human coronavirus 229E. Subsequently, the compounds were further tested in vitro using a cytopathic inhibition assay to assess their antiviral activity against both human Influenza (H1N1) and human coronavirus (HCoV-229E). Diphenyl ((2-(5-cyano-6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl) hydrazinyl) (furan-2-yl) methyl) phosphonate (3f) and diethyl ((2-(5-cyano-6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl) hydrazinyl) (1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl) methyl) phosphonate (4e) were demonstrated direct inhibition activity against Influenza A Neuraminidase and RNA-dependent RNA polymerase. This was supported by their highly favorable binding energies in-silico, with top-ranked values of -12.5 kcal/mol and -14.2 kcal/mol for compound (3f), and -13.5 kcal/mol and -9.89 kcal/mol for compound (4e). Moreover, they also displayed notable antiviral efficacy in vitro against both viruses. These compounds demonstrated significant antiviral activity, as evidenced by selectivity indices (SI) of 101.7 and 51.8, respectively against H1N1, and 24.5 and 5.1 against HCoV-229E, respectively.